Julian Sturdy – 2015 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Julian Sturdy on 2015-12-08.

To ask the Secretary of State for Health, when he expects Orkambi to be appraised by NICE.

George Freeman

The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance on the use of Orkambi (lumacaftor in combination with ivacaftor) for the treatment of cystic fibrosis in people who are homozygous for the F508del mutation. NICE’s anticipated publication date for this guidance is July 2016. Further information is available at:

www.nice.org.uk/guidance/indevelopment/gid-tag530